MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Chemoimmunotherapy or BTK inhibition for patients with CLL

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL

Inhibition of NADK strongly inhibits T-ALL cells from growing

ASCO 2019 and vision for cancer control

Better education about breast cancer treatment in Africa

Improving radiotherapy access in Africa

The Global Health Catalyst initiative

Genomic trends across the African Diaspora for breast cancer

Highlights from ASCO 2019

Metabolic vulnerability in NOTCH-driven T cell acute lymphoblastic leukaemia

MLL-rearranged acute lymphoblastic leukaemia